RNA polymerase I-driven reverse genetics system for enterovirus 71 and its implications for vaccine production
© Meng et al.; licensee BioMed Central Ltd. 2012
Received: 1 March 2012
Accepted: 4 October 2012
Published: 17 October 2012
Enterovirus 71 (EV71) is a virus that causes from mild hand, foot and mouth disease (HFMD) to severe neurological complications and deaths in infants and young children. Effective antiviral agents and vaccines against EV71 are not available. However, Vero cell-based chemically inactivated EV71 vaccines could be developed soon based on the success of inactivated polio vaccine. Like poliovirus, EV71 has a positive single-stranded RNA genome of about 7400 nucleotides which contains a single open reading frame (ORF) flanked by conserved and untranslated regions at both the 5′ and 3′ ends.
The universal amplification of the full length genome of EV71 regardless of its genetic diversity, and the subsequent construction of a human RNA polymerase I-driven reverse genetics (RG) system to produce pure virus stocks in Vero cell within 10 days were described. The rescued viruses were characterized by DNA sequencing, cytopathic effect (CPE) and indirect fluorescent assay (IFA) in comparison with the wild-type viruses. Moreover, the rescued viruses grew to high titers and retained the same immunogenicity as the wild-type viruses.
We have established a simplified method to rescue RG EV71 virus from diverse clinical isolates with detailed genetic information and to prepare virus stocks in only 10 days. This method could accelerate EV71 vaccine development.
KeywordsEnterovirus 71 Universal RT-PCR Reverse genetics Vaccine
Enterovirus 71 (EV71) belongs to the enterovirus genus of the picornavirus family, which also includes coxsackievirus A16 (CA16), poliovirus and echovirus . EV71 has a small and nonenveloped icosahedral capsid comprising of four structural proteins (VP1 to VP4) and surrounding a genome of ~7,400 nt single stranded RNA. The viral genome contains a single large open reading frame (ORF) encoding a polyprotein which is subsequently cleaved into multiple mature proteins by virally encoded proteases. The ORF is flanked by 5′- and 3′- untranslated regions (5′- and 3′- UTR) which are highly conserved and play essential roles during the viral life cycle. There is also a short poly A tail following the 3′-UTR [2, 3]. The EV71 genome mutates rapidly because of the low fidelity of its RNA dependent RNA polymerase [4, 5]. Based on a phylogenetic tree of VP1 gene sequences, EV71 is divided into three major genogroups (denoted A, B and C), and various subgenogroups within genogroups B (B1 to B5) and C (C1 to C5) [4–6]. Predominant subgenotypes currently circulating are B5, C1, C4 and C5; and different genotypes of EV71 strains may co-circulate in the same area. Additionally, intra- or inter-genogroup recombination and positive selection contribute to the genetic and antigenic diversity of EV71 [7, 8].
EV71 is a causative agent of hand, foot and mouth disease (HFMD), most frequently affecting infants and children below 6 years old. Infection with EV71 is usually mild but occasionally leads to neurological manifestations ranging from aseptic meningitis to acute flaccid paralysis and lethal brainstem encephalitis [9, 10]. Large outbreaks of EV71 with fatal cases have been seen in the Asia-Pacific region since the 1990s [2, 6, 11]. Unfortunately, no effective medications or prophylactic vaccines are currently available for controlling EV71 infection. Mass vaccination of formaldehyde inactivated or adapted live attenuated EV71, grown in African green monkey kidney (Vero) cell, would be a favorable method to control EV71 epidemics based on the successful experience in poliovirus vaccination . Therefore, the selection and characterization of EV71 vaccine strains with high growth titers and broad cross-subgenogroup virus neutralizing antibody responses are urgent for vaccine development .
Reverse genetics (RG) permits the use of complementary DNA (cDNA) copies of viral RNA genome to rescue virus with detailed features of viral genetic diversity, antigenicity and virulence. RG systems using T7 or S6 RNA polymerase to synthesize infectious RNA in vitro from cDNA have been developed for many picornaviruses, including EV71 [14, 15]. In addition, RNA polymerase I-based RG systems which ensure the precise and efficient transcription of viral genomes in vivo have been described for influenza virus , HFMD  and EV71 .
Here, we have developed a robust RT-PCR method for the universal amplification of whole EV71 genome and a novel human RNA polymerase I (hPolI)-driven RG system for the rapid production of pure and immunogenic stock in Vero cell. The implications of these findings are discussed.
To determine whether RG viruses were rescued and infectious after directly transfection of recombinant plasmids, both transfected and RG virus infected cells were analyzed by CPE and IFA. Here, only EV71-B5 was presented as an example because other EV71 strains showed a similar pattern. After the transfection of the recombinant plasmid pJET-hPolI/mTer-EV71-B5, we did not observed the CPE under light microscopy at the third post transfection day because little RG viruses were generated from EV71-B5 cDNA constructs. However, the CPE was obvious when fresh Vero cells were infected by rescued RG EV71-B5 from transfection (P1 infection, Figure 1C). Furthermore, IFA results showed that transfected or RG virus infected cells were positive by immunostaining with guinea pig anti EV71 serum (Figure 1C). Additionally, the viral proteins VP1 and 3D were both detectable after the transfection and infection using mouse monoclonal antibodies 1D9 and 4B12 (Additional file 1). Therefore, the hPolI promoter was active and the EV71 genomic RNA was successfully transcribed inside Vero cell, and the rescued RG EV71-B5 viruses were infectious and produced viral proteins inside cells.
Comparison of immunogenicity of formalin-inactivated RG and wild-type (wt) viruses
Log2 (titer of neutralizing antibody) against (mean (SD)):
In our previous paper, we described an hPolI-driven RG system for generating infectious EV71 from synthetic cDNA in RD cell . In this study, we tried a similar system to rescue EV71 viruses in Vero cell for vaccine production. This RG system takes advantage of host RNA polymerase I promoter to generate exact EV71-like vRNA with precise initiation and termination inside Vero cell. Unlike to T7 or SP6 polymerase-driven RG systems, no extra bases were added during in vivo transcription at the 5′ and 3′ ends of viral RNA transcripts (Figure 1B). Those extra bases had been reported to impede the rescue of some RG viruses [22, 23].
Traditionally, potential EV71 vaccine strains are firstly selected from hundreds of clinical isolates which are usually cultured in RD cell. Candidate strains with low virulence and high immunogenicity are then attenuated in Vero cell which has been approved for EV71 vaccine production [13, 24]. Plaque screening and further subculture are then performed to select and purify the candidate strains with higher growth titers. The genomic stability and immunogenicity of candidate strains in passages have to be maintained. The whole procedure is time-consuming and haphazard, and contamination with pathogens derived from the clinical samples or non-validated cell culture systems can occur . In contrast, our hPolI-driven RG system our procedure was faster because it excludes the chance of contamination by other pathogens resulting in pure virus stock from an identical cDNA construct in 10 days (Figure 3). Additionally, this method is less haphazard because the exact genome sequence for each clone was known from the beginning which permits genomic comparison and engineering to exclude clones carrying virulence determinants or to introduce desired traits.
In conclusion, we have established a robust RT-PCR method to amplify the entire genome of EV71, regardless of its subgenogroup, with a pair of universal primers, and used these amplicons for both high-throughput sequencing and direct incorporation into a reverse-genetics plasmid containing an hPolI promoter to rapidly produce infectious EV71 seed stock. The whole procedure took 10 days only. Furthermore, the rescued RG viruses retained the same immunogenicity as wild type viruses in mouse. This RG system greatly simplifies the isolation and selection of EV71 vaccine candidates and could accelerate the development of EV71 vaccines.
Materials and methods
Cell culture and virus propagation
Human rhabdomyosarcoma (RD) cell and Vero cell were maintained in Minimum Essential medium (MEM, Gibco) containing 10% fetal bovine serum (FBS, iDNA) at 37°C in the presence of 5% CO2. The EV71 strains used in this study were EV71-A (BrCr, U22521.1), EV71-B2 (7432/MS/87, U22522.1), EV71-B4 (HFMD41 /SIN), EV71-B5 (NUH0083/SIN/08, FJ461781), EV71-C1 (Y90-3761, AB433864), EV71-C2 (1585-Yamagata-01, AB177812), EV71-C4 (75-Yamagata-03, AB177813), EV71-C5 (3437/SIN/06, GU222654), and some unknown EV71 strains from Malaysia labeled #363, #366, #396, #482, and #557. All EV71 wild type strains were isolated from patients and propagated in RD cell. All reverse genetics viruses were rescued in Vero cells.
EV71 genomic cDNA amplification
Viral RNA was extracted from culture supernatant using RNeasy mini kit (Qiagen). The reverse transcription reaction was performed for 1 hour at 42°C with RevertAid First Strand cDNA Synthesis Kit (Fermentas) using viral RNA as the template and oligo(dT)18 as primer. The full-length genomic cDNAs of EV71 were amplified using PfuUltra II Hotstart PCR Master Mix (Agilent Technologies, Inc) and EV71 specific universal primers EV71-Uni-F (5′-GGCCGCCGGGTTATTTTAAAACAGCCTGTGGGTTG) and EV71-Uni-R (5′-CCGAAGTTGGGGGGGTTTTTTTTTTTTTTTTTTTTTTTTTTGCTATTCYGGTTATAAC). The reaction parameters were as follows: an initiation step at 94°C for 2 min, followed by 40 cycles (94°C for 15 sec, 52°C for 20 sec and 72°C for 4 min) and a final extension step at 72°C for 5 min. The amplicons were analyzed by gel electrophoresis and purified using QIAquick gel Purification Kit (Qiagen).
Construction of recombinant plasmids for RG EV71
The human RNA polymerase I (hPolI) promoter and murine terminator cassette sequence were amplified from sap/pol vector and then inserted into pJET1.2 vector as described previously . The plasmid pJET-hPolI/mTer was linearized by PCR using primers pJET-HPol1mTer-f (5′-CCCCCCCAACTTCGGAGGTC) and pJET-hPol1mTer-r (5′- AATAACCCGGCGGCCCAAAATG). The EV71 genomic cDNA amplicons were joined with linearized pJET-hPolI/mTer using In-Fusion HD cloning Kit (Agilent Technologies, Inc). 5 μl of the cloning reaction was transformed into 100 μl of competent XL1-Blue E. coli by heat shock. The recombinant plasmids were selected by PCR screening with primers pJET-f (5′-CGACTCACTATAGGGAGAGCGGC) and EV71-VP1-r (5′-GCYCCRTATTC AAGRTCTTTCTC), and their correctness and genotypes were confirmed by DNA sequencing and phylogenetic tree analysis, respectively.
Transfection and infection
A mixture of 1 μg of each recombinant plasmid and 2.5 μl Lipofectamine 2000 reagent (Invitrogen) was transfected into 5x105 Vero cells in 2 ml medium in 6-well plates. The transfected cells were lysed after 3 days by 3 freeze-thaw cycles and the supernatant containing viruses was collected for further passage. The rescued viruses were harvested after 4 days and their titers were determined as 50% tissue culture infective dose (TCID50) according to cytopathic effect (CPE) in Vero cell using the Reed and Muench formula.
One-step growth curve of rescued viruses
The growth kinetics of rescued viruses was determined in subconfluent Vero cell culture in 1 ml medium in 24-well plates. The cells were incubated with rescued viruses at a multiplicity of infection (MOI) of 1 for 1 h at 37°C, and then washed with PBS 3 times and cultured in MEM with 2% FBS. The infected cells were frozen at day 2, 3, 4, 5, 6 and 7 post-infection and stored at -80°C. After 3 freeze-thaw cycles, the virus concentrations were titrated by TCID50 assay.
Indirect immunofluorescence assay (IFA)
Vero cells transfected with the recombinant plasmids or infected with rescued RG virus were grown in 96-well plates. The cells were fixed with 4% PFA after 24 h and incubated with guinea pig anti EV71 serum (produced in house) diluted 1:500 for 30 min at 37°C. Then the cells were washed and incubated with fluorescein isothiocyanate (FITC)-labeled goat anti-guinea pig IgG (Dako) diluted 1:200 for another 30 min. Finally, the cells were rinsed with PBS and visualized under a fluorescent microscope (Olympus).
Immunogenicity of RG viruses in mouse
The rescued and wild type viruses in Vero cell were harvested at 5th day post-infection and purified by ultracentrifugation as described previously . The purified viruses were then inactivated with 0.2% formalin (v/v) at 37°C for 3 days and stored at 4°C, and the amount of viral protein was determined using Bradford assay (Bio-Rad Laboratories, USA). For immunization, groups of 6 female BALB/c mice (6 to 8-week old) were each intraperitoneally immunized with 25 μg inactivated viruses in 200 μl of 0.1 M aluminum phosphate (Sigma) or PBS as a negative control. The mice were boosted with the same dose 2 weeks after priming. The sera were then collected one week after the boost and the presence of neutralizing antibodies against EV71 was assayed by an in vitro microneutralization assay . Briefly, 25 μl of serial twofold dilutions of heat inactivated serum samples were mixed with 25 μl of 100 TCID50 of virus, and the neutralization antibody titer was determined as the highest dilution of serum that protected 50% of Vero cell cultures.
All animal experiments were carried out in accordance with the Guides for Animal Experiments of the National Institute of Infectious Diseases (NIID), and experimental protocols were reviewed and approved by the Institutional Animal Care and Use Committee of the Temasek Life Sciences Laboratory, Singapore (Project Approval no. TLL-11-002).
Hand foot and mouth disease
Open reading frame
Human RNA polymerase I
Multiplicity of infection
50% tissue culture infection dose
Minimum essential medium
African green monkey kidney cell.
We thank Prof. Vincent T.K. Chow (National University of Singapore) and Dr. Kaw-Bing Chua (TLL) for EV71 clinical isolates. This study was supported by grant from Temasek Life Sciences Laboratory Ltd (TLL), Singapore.
- Pallansch MA, Roos RP: Enteroviruses: poliovirus, coxsackieviruses, echoviruses, and newer enteroviruses. Fields virology. Edited by: Knipe DM, Howley PM, Griffin DE, Martin MA, Lamb RA, Roizman B. 2000, Philadelphia, PA: Lippincott Williams & Wilkin, 723-775. vol. 1, 4
- Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Mong HO: Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010, 10: 778-790. 10.1016/S1473-3099(10)70194-8.PubMedView Article
- Brown BA, Pallansch MA: Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res. 1995, 39: 195-205. 10.1016/0168-1702(95)00087-9.PubMedView Article
- Tee KK, Lam TT, Chan YF, Bible JM, Kamarulzaman A, Tong CY, Takebe Y, Pybus OG: Revolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J Virol. 2010, 84: 3339-3350. 10.1128/JVI.01019-09.PubMedPubMed CentralView Article
- Brown BA, Oberste MS, Alexander JP, Kennett ML, Pallansch MA: Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol. 1999, 73: 9969-9975.PubMedPubMed Central
- Mcminn P, Lindsay K, Perara D, Chan HM, Chan KP, Cardosa MJ: Phylogenetic analysis of enterovirus 71 strains isolated during linked epidemics in Malaysia, Singapore, and Western Australia. J Virol. 2001, 75: 7732-7738. 10.1128/JVI.75.16.7732-7738.2001.PubMedPubMed CentralView Article
- Simmonds P, Welch J: Frequency and dynamics of recombination within different species of human enteroviruses. J Virol. 2006, 80: 483-493. 10.1128/JVI.80.1.483-493.2006.PubMedPubMed CentralView Article
- Chen X, Zhang Q, Li J, Can W, Zhang JX, Zhang L, Zhang W, Shao ZJ, Yan Y: Analysis of recombination and natural selection in human enterovirus 71. Virol. 2010, 398: 251-261. 10.1016/j.virol.2009.12.007.View Article
- Alexander JP, Baden L, Pallansch MA, Anderson LJ: Enterovirus 71 infections and neurologic disease-United States, 1977–1991. J Infect Dis. 1994, 169: 905-908. 10.1093/infdis/169.4.905.PubMedView Article
- Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T: Clinical features, diagnosis and management of human enterovirus 71 infection. Lancet Neurol. 2010, 9: 1097-1105. 10.1016/S1474-4422(10)70209-X.PubMedView Article
- Xu J, Qian Y, Wang SX, Serrano JG, Li W, Huang ZH, Lu S: EV71: an emerging infectious disease vaccine target in the far east?. Vaccine. 2010, 28: 3516-3521. 10.1016/j.vaccine.2010.03.003.PubMedView Article
- Ong KC, Devi S, Cardosa MJ, Wong KT: Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol. 2010, 84: 661-665. 10.1128/JVI.00999-09.PubMedPubMed CentralView Article
- Chang JY, Chang CP, Tsai HH, Lee CD, Lian WC, Su IJ, Sai IH, Liu CC, Chou AH, Lu YJ, Chen CY, Lee PH, Chiang JR, Chong PC: Selection and characterization of vaccine strain for enterovirus 71 vaccine development. Vaccine. 2012, 30: 703-711. 10.1016/j.vaccine.2011.11.087.PubMedView Article
- Arita M, Shimizu H, Nagata N, Ami Y, Suzaki Y, Sata T, Iwasaki T, Miyamura T: Temperature-sensitive mutants of enterovirus 71 show attenuation in cynomolgus monkeys. J Gen Virol. 2005, 86: 1391-1401. 10.1099/vir.0.80784-0.PubMedView Article
- Han JF, Cao RY, Tian X, Yu M, Qin ED, Qin CF: Producing infectious enterovirus type 71 in a rapid strategy. Virol J. 2010, 7: 116-120. 10.1186/1743-422X-7-116.PubMedPubMed CentralView Article
- Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG: A DNA transfection system for generation of influenza a virus from eight plasmids. Proc Natl Acad Sci USA. 2000, 97: 6108-6113. 10.1073/pnas.100133697.PubMedPubMed CentralView Article
- Chang Y, Zheng H, Shang Y, Jin Y, Wang G, Shen X, Liu X: Recovery of infectious foot-and-mouth disease virus from full-length genomic cDNA clones using RNA polymerase i system. Acta Biochem Biophys Sin. 2009, 41: 998-1007. 10.1093/abbs/gmp093.View Article
- Meng T, Kolpe AB, Kiener TK, Chow VT, Kwang J: Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human enterovirus 71 strains in mice. PLoS One. 2011, 6: e21757-10.1371/journal.pone.0021757.PubMedPubMed CentralView Article
- Liu G, Liu Z, Xie Q, Chen Y, Bao H, Chang H, Liu X: Generation of an infectious cDNA clone of an FMDV strain isolated from swine. Virus Res. 2004, 104: 157-164. 10.1016/j.virusres.2004.04.002.PubMedView Article
- Fu J, Stein S, Rosenstein L, Bodwell T, Routbort M, Semler BL, Ross RP: Neorovirulence determinants of genetically engineered Theiler viruses. Proc Nati Acad Sci USA. 1990, 87: 4125-4129. 10.1073/pnas.87.11.4125.View Article
- Hawkins PR, Jin P, Fu GK: Full-length cDNA synthesis for long-distance RT-PCR of large mRNA transcripts. Biotechniques. 2003, 34: 768-773.PubMed
- Sarnow P: Role of 3′-end sequences in infectivity of poliovirus transcripts made in vitro. J Virol. 1989, 63: 467-470.PubMedPubMed Central
- Janda M, French R, Ahlquist P: High efficiency T7 polymerase synthesis of infectious RNA from cloned brome mosaic virus cDNA and effects of 5′ entensions on transcript infectivity. Virology. 1987, 158: 259-262. 10.1016/0042-6822(87)90265-0.PubMedView Article
- Liu CC, Guo MS, Lin FH, Hsiao KN, Chang KH, Chou AH, Wnag YC, Yang CS, Chong PC: Purification and characterization of enterovirus 71 viral particles produced from Vero cells grown in a serum-free microcarrier bioreactor system. PLoS One. 2011, 6: e20005-10.1371/journal.pone.0020005.PubMedPubMed CentralView Article
- Nicolson C, Major D, Wood JM, Robertson JS: Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine. 2005, 23: 2943-2952. 10.1016/j.vaccine.2004.08.054.PubMedView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.